News

AbbVie’s venetoclax has picked up another breakthrough therapy status in the US, this time in combination with Roche’s rituximab as a treatment for patients with relapsed/refractory chronic lymphocytic leukaemia.

Novartis has launched its eagerly-awaited and potentially revolutionary heart pill Entresto in the UK, giving patients with a certain form of heart failure a much needed new treatment approach that offers a significant mortality benefit over standard therapy.

Johnson & Johnson has announced a revamp of its medical devices division that could see a job cull of around 3,000 positions, in a bid to generate cost-savings of up to $1 billion as the sector’s growth continues to slow.

The British Medical Association has called off next week’s planned industrial action by junior doctors following “early progress” in conciliatory talks with the government over its plans for the new working contract.

Lilly and Incyte have filed for US approval of the experimental JAK inhibitor baricitinib as a treatment for moderately-to-severely active rheumatoid arthritis.

The final entry deadline for the International Clinical Researcher of the Year 2016 is Friday 22 January. PharmaTimes Media is delighted to announce an increase in the number of clinical researchers taking part in this prestigious international competition

The deadline for entry essays is in ONE WEEK, on the 29 January 2016, so don’t delay!

Acorda Therapeutics is snapping up Finnish biotech Biotie Therapies in a deal valued at around $363 million, giving the firm a much stronger footprint in the Parkinson’s disease field.

The number of prescriptions dispensed in England for approved medicines to treat Alzheimer’s disease is six times higher than a decade ago, official figures have revealed.

Manchester is rolling out the biggest seven-day GP access scheme in the country, offering 600,000 people appointments on evenings and weekends.

UCL has launched a £50-million Technology Fund to help drive commercialisation of its multidisciplinary research discoveries over the next five years. 

European regulators have approved the first biosimilar version of Pfizer/Amgen’s multi-billion-dollar anti-inflammatory therapy Enbrel, made by Samsung Bioepis, a joint venture between Samsung Biologics and Biogen.

Novartis’ Cosentyx is the first IL-17 inhibitor to win US approval for ankylosing spondylitis and psoriatic arthritis, offering a new approach to treating two of the most common inflammatory joint conditions, for which there remains high unmet need.

US regulators are undertaking an accelerated review of Eisai’s lenvatinib as a treatment for patients with kidney cancer.

The National Health Service is planning its own sugar tax throughout its hospitals and health centres to help combat obesity, chief executive Simon Stevens has told The Guardian.